VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

gp100:209-217(210M) peptide vaccine

Vaccine Information

Vaccine Name: gp100:209-217(210M) peptide vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007608
Type: Peptide
Status: Clinical trial
Immunization Route: Intramuscular injection (i.m.)

Host Response

Human Response

Vaccine Immune Response Type: VO_0003057
Immune Response: Levels of CD4+foxp3+ cells were higher in patients who had a clinical response to treatment than in those who did not have a response. In vitro studies of T-cell reactivity showed that some patients in the vaccine group had an increase in circulating gp100 reactive T cells after vaccination (Schwartzentruber et al., 2011).

References

Schwartzentruber et al., 2011: Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England journal of medicine. 2011; 364(22); 2119-2127. [PubMed: 21631324].